{
    "ticker": "AUPH",
    "name": "Aurinia Pharmaceuticals Inc.",
    "description": "Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for the treatment of autoimmune diseases. Founded in 2013 and headquartered in Victoria, British Columbia, Canada, Aurinia focuses on advancing its lead product candidate, voclosporin, a novel calcineurin inhibitor, which is being developed for the treatment of lupus nephritis, a severe complication of systemic lupus erythematosus. Voclosporin has shown promising results in clinical trials, offering new hope to patients suffering from this debilitating condition. The company is committed to addressing significant unmet medical needs and improving the lives of patients through its research and development efforts. Aurinia's pipeline also includes other potential therapies targeting various autoimmune disorders, highlighting its strategic focus on this therapeutic area. By leveraging cutting-edge science and clinical expertise, Aurinia aims to bring transformative therapies to market and establish itself as a leader in the biopharmaceutical industry.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Victoria, British Columbia, Canada",
    "founded": "2013",
    "website": "https://www.auriniapharma.com",
    "ceo": "Peter Greenleaf",
    "social_media": {
        "twitter": "https://twitter.com/AuriniaPharma",
        "linkedin": "https://www.linkedin.com/company/aurinia-pharmaceuticals-inc/"
    },
    "investor_relations": "https://ir.auriniapharma.com",
    "key_executives": [
        {
            "name": "Peter Greenleaf",
            "position": "CEO"
        },
        {
            "name": "David A. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Development",
            "products": [
                "Voclosporin"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aurinia Pharmaceuticals Inc. | Innovating Autoimmune Disease Treatments",
        "meta_description": "Aurinia Pharmaceuticals Inc. focuses on developing innovative therapies for autoimmune diseases, including lupus nephritis. Learn about their lead product voclosporin and ongoing clinical trials.",
        "keywords": [
            "Aurinia Pharmaceuticals",
            "Voclosporin",
            "Lupus Nephritis",
            "Autoimmune Diseases",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Aurinia Pharmaceuticals known for?",
            "answer": "Aurinia Pharmaceuticals is known for its development of voclosporin for the treatment of lupus nephritis and other autoimmune diseases."
        },
        {
            "question": "Who is the CEO of Aurinia Pharmaceuticals?",
            "answer": "Peter Greenleaf is the CEO of Aurinia Pharmaceuticals Inc."
        },
        {
            "question": "Where is Aurinia Pharmaceuticals headquartered?",
            "answer": "Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada."
        },
        {
            "question": "What is voclosporin?",
            "answer": "Voclosporin is a novel calcineurin inhibitor being developed for the treatment of lupus nephritis."
        },
        {
            "question": "When was Aurinia Pharmaceuticals founded?",
            "answer": "Aurinia Pharmaceuticals was founded in 2013."
        }
    ],
    "competitors": [
        "NVAX",
        "AMGN",
        "GILD",
        "ABBV"
    ],
    "related_stocks": [
        "BMY",
        "JNJ",
        "PFE",
        "MRK"
    ]
}